Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 12/20 | 0.38 |
| ▸ | CHRM3 | P20309 | 12/20 | 0.38 |
| ▸ | CHRM2 | P08172 | 6/20 | 0.38 |
| ▸ | CHRM5 | P08912 | 10/20 | 0.35 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.35 |
| ▸ | NTMT1 | Q9BV86 | 3/20 | 0.34 |
| ▸ | UGCG | Q16739 | 1/20 | 0.34 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16933677 | 0.83 | CHRM5 (0.40) | CHRM1CHRM3CHRM2CHRM5 | |
| SCHEMBL16933657 | 0.82 | CHRM5 (0.41) | CHRM1CHRM3CHRM2CHRM5 | |
| SCHEMBL16933679 | 0.81 | KDM1A (0.33) | CHRM1CHRM3CHRM2CHRM5 | |
| SCHEMBL16933460 | 0.74 | CA2 (0.31) | — | |
| SCHEMBL16007057 | 0.72 | CHRM1 (0.39) | CHRM1CHRM3CHRM2CHRM5CHRM4 | |
| SCHEMBL12614899 | 0.72 | CHRM3 (0.38) | CHRM1CHRM3CHRM2CHRM5NTMT1 | |
| SCHEMBL16006982 | 0.72 | CYP3A4 (0.42) | CHRM1CHRM3CHRM2CHRM5NTMT1 | |
| SCHEMBL16006980 | 0.72 | CHRM1 (0.37) | CHRM1CHRM3CHRM2CHRM5NTMT1 | |
| SCHEMBL16933446 | 0.71 | CHRNA7 (0.41) | CHRM1CHRM3CHRM2CHRM5CHRM4 | |
| SCHEMBL16007054 | 0.70 | CHRM1 (0.38) | CHRM1CHRM3CHRM2CHRM5NTMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150210681-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2015-07-30 | — | — | US | claimed |
| EP-4559918-A2 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2025-05-28 | — | — | EP | disclosed |
| EP-4098654-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | Genzyme Corporation (US) | 2022-12-07 | — | — | EP | disclosed |
| US-9139580-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2015-09-22 | — | — | US | disclosed |
| US-9126993-B2 | Glucosylceramide synthase inhibitors | GENZYME CORPORATION (US) | 2015-09-08 | — | — | US | disclosed |
| US-20150210681-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2015-07-30 | — | — | US | disclosed |
| US-20140371460-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION | 2014-12-18 | — | — | US | disclosed |
| US-20140255381-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GENZYME CORPORATION (US) | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150210681-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | CHRM1 4870/4885CHRM3 4832/4885CHRM2 4853/4885 |
| US-20140371460-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | CHRM1 4879/4885CHRM3 4870/4885CHRM2 4875/4885 |
| US-20140255381-A1 | GLUCOSYLCERAMIDE SYNTHASE INHIBITORS | GBA1, GBA2, GAA | CHRM1 4879/4885CHRM3 4870/4885CHRM2 4875/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.